May 13, 2023, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) successfully held The 8th Pulmonary Arterial Hypertension Summit in Chongqing. With the theme of “Protecting Heart and Lungs For Health”, the forum aimed to promote academic exchanges at home and abroad, and to improve the diagnosis and treatment of pulmonary arterial hypertension.

May 9, 2023, the high-profile 86th PharmChina was grandly opened at the Qingdao International Expo Center on the theme "Building a new innovative and inclusive ecology of pharmaceutical and health". Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) participated in the event.

April 24, 2023, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) announced that its in-licensed product Natulan® (Procarbazine Hydrochloride Capsules, formerly known as Procarbazine), was successfully launched in China and was distributed from its Guangzhou Nansha manufacturing site across the country.

Recently, the Guangdong High-tech Association granted the certificates of “Guangdong Famous High-tech Products” for 2022. The Sodium Phenylbutyrate Granules, an in-house developed product of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), won the award by virtue of its outstanding innovation capacity, advanced technology, reliable quality and good market prospect.

Recently, Southern Metropolis Daily interviewed Dr. LI Xiao Yi Benjamin, the Founder and Director of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), to discuss the current situation of domestic ophthalmic disease treatment and drug market.

On March 29, 2023, the preliminary bidding result of the eighth round of the national drug bulk-buying launched by the National Healthcare Security Administration was released. Zhaoke Pharmaceutical (Hefei) Company Limited, a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), participated in the bidding and its product Nadroparin Calcium Injection won the bid as a generic drug approved under the new Registration Classification of Chemical Drugs. This is another product following Fondaparinux Sodium Injection that was selected in the government’s centralized medical procurement program.

March 15, 2023, the Guangdong-Hong Kong-Macau Greater Bay Area New Direction for Economic Development Conference cum Gold Pilot Award 2022, co-organized by Hong Kong Trade Development Council (HKTDC) and Hong Kong Chamber of Commerce in Guangdong (HKCCGD) was successfully held in Shangri-La Hotel, Guangzhou. Guangzhou Zhaoke Lian Fa Pharmaceutical Limited, a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was honoured with “Excellence Enterprise Award”. Awardees included Chow Sang Sang Jewellery, Lee Kum Kee, Hong Kong Broadband Network etc.

Recently, the Hefei Municipal Government announced the result of the 8th Hefei City Industrial Achievements in Technology and Innovation. The development of Antiplatelet Thrombolysin by Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was honoured with second prize. The representative of the Group attended the High-tech Industrial Development Zone Awards Ceremony and received the prize.

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) attained again the Caring Company Award Logo by The Hong Kong Council of Social Service (HKCSS) for three consecutive years in recognition of its commitment to caring for the community, employees and environment.

Treprostinil Injection, Teglutik® and Trittico®, the commercialized products of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) have been included for the first time into the updated National Reimbursement Drug List (the “NRDL”) issued by the China National Healthcare Security Administration on 18 January 2023 and will be officially implemented from 1 March 2023. Together with the other 6 products in the list, a total of 9 products of the Group have been included in the updated NRDL. Among 111 products included for the first time in this updated NRDL, 7 of which are from rare disease area and the Group’s Treprostinil Injection and Teglutik® have taken up 2 places thereof. Lee’s Pharm firmly believed that the newly inclusion of these specialty drugs into the updated NRDL will help the Group to further enhance the affordability and accessibility thereof among patients in rare disease and mental health areas.

Hong Kong, December 22, 2022, the “STEM Experience Program for Secondary Students——Kanya Lee Scholarship Recognition Ceremony 2022” was successfully held in Hyatt Regency Hong Kong, Tsim Sha Tsui. Established in 2021, the Kanya Lee Scholarship Program, co-organized with Caritas School Social Work Service, aims at providing support to the secondary students with economic burden to fully develop their potentials and talents, as well as to explore the future. Apart from the one-off scholarship and monthly subsidy, the Group provides practical internship opportunities for students who are interested in scientific and research field. To date, a total of 59 secondary school students have been benefited from this scholarship program.

Hong Kong, December 14-17, 2022, the International Convention for Biotechnology in Hong Kong 2022 (BIOHK2022), co-organized by the Hong Kong Biotechnology Organization, BayHelix Group and Ausvic Capital was successfully held in the Hong Kong Convention and Exhibition Centre. As the first international biotech exhibition organized in Hong Kong, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), the Diamond Sponsor, actively participated in the BIOHK2022, which intends to drive Hong Kong biotechnology development, enhance international business connections and create investment opportunities.